Detalles de la búsqueda
1.
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Ann Rheum Dis
; 83(4): 464-474, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38233103
2.
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Rheumatol Int
; 44(2): 249-261, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37815625
3.
Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.
Clin Exp Rheumatol
; 36(1): 102-109, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-28850029
4.
High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
Clin Exp Rheumatol
; 36(2): 254-262, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29148406
5.
Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
Clin Exp Rheumatol
; 34(6): 999-1005, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27749220
6.
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis.
RMD Open
; 10(1)2024 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38242549
7.
Cost of Illness, Quality of Life, and Work Productivity in Axial Spondyloarthritis Patients Receiving Biological Treatments in Greece.
Mediterr J Rheumatol
; 34(1): 37-43, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37223606
8.
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.
Cells
; 12(24)2023 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38132128
9.
Comorbidities Burden and Implementation of the Treat-to-Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides.
Mediterr J Rheumatol
; 34(4): 581-587, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38282943
10.
Population Characteristics, Symptoms, and Risk Factors of Idiopathic Chilblains: A Systematic Review, Meta-Analysis, and Meta-Regression.
Biology (Basel)
; 11(11)2022 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36421364
11.
Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients.
Arthritis Res Ther
; 24(1): 206, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36008868
12.
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Arthritis Res Ther
; 24(1): 132, 2022 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35655317
13.
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Front Immunol
; 13: 1074044, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36685524
14.
Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.
J Rheumatol
; 48(1): 48-57, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32238520
15.
Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group.
Arthritis Res Ther
; 22(1): 226, 2020 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32993800
16.
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Mediterr J Rheumatol
; 31(1): 87-91, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32411939
17.
Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
J Rheumatol
; 45(6): 785-794, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29606666
18.
Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Semin Arthritis Rheum
; 43(4): 447-57, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24012040
Resultados
1 -
18
de 18
1
Próxima >
>>